Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
3 Biotech Stocks That Could Boom or Bust in Q1
06:00am, Tuesday, 01'st Feb 2022
The biotech industry is exploding. Biotech stocks provide lots of opportunities for investors who are taking a risk on the medicine's future.
Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer
01:53pm, Monday, 31'st Jan 2022
Regeneron (REGN) and partner Sanofi voluntarily withdraw the supplemental biologics license application for Libtayo in second-line treatment of advanced cervical cancer.
EMA OKs expanded use of Regeneron/Sanofi''s asthma med Dupixent in kids aged 6 to 11
10:50am, Monday, 31'st Jan 2022 Seeking Alpha
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announce that the EMA''s Committee for Medicinal Products for Human Use ((CHMP)) has adopted a positive opinion, recommending to extend
CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation
06:44am, Monday, 31'st Jan 2022
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending expanding the use of Dupixent (dupilumab). [ALERT] Nic Chahine share
Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
04:09pm, Friday, 28'th Jan 2022
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron, Sanofi withdraw Libtayo application in cervical cancer (NASDAQ:REGN)
12:32pm, Friday, 28'th Jan 2022 Seeking Alpha
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announce the voluntary withdrawal of the supplemental Biologics License Application (sBLA) for Libtayo (cemiplimab-rwlc) as a
Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use
10:31am, Friday, 28'th Jan 2022
Regeneron Pharmaceuticals Inc REGN and its partner Sanofi SA SNY have voluntarily withdrawn their application with the FDA for the expanded use of Libtayo in patients with advanced cervical canc
Regeneron, Sanofi withdraw application for Libtaya as a cervical cancer treatment in the U.S.
07:32am, Friday, 28'th Jan 2022
Shares of Regeneron Pharmaceuticals Inc. REGN, +0.57% were down 0.1% in premarket trading on Friday after the company and Sanofi SNY, +3.00% said they will no longer seek Food and Drug Administration
LABU - A Compelling Biotech Trade
04:24pm, Wednesday, 26'th Jan 2022
LABU - A Compelling Biotech Trade
FDA Limits Use of Regeneron & Lilly's COVID Antibody Cocktails
12:23pm, Tuesday, 25'th Jan 2022
The FDA modifies EUA for COVID-19 antibody cocktail drugs of Regeneron (REGN) and Lilly (LLY), limiting their use to treat individuals with COVID-19 infection from non-Omicron variants.
Large Cap Pharma, Biotech Stocks Down on Regulatory Updates
11:35am, Tuesday, 25'th Jan 2022
Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
10:28pm, Monday, 24'th Jan 2022
Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authori
FDA Rescinds Authorization For Covid Antibody Treatments By Regeneron, Eli Lilly
06:38pm, Monday, 24'th Jan 2022
Monoclonal antibody treatments by Regeneron and Eli Lilly proved ineffective against the omicron variant, the FDA said.
FDA to restrict COVID-19 antibody therapies from Regeneron and Eli Lilly - WaPo
05:14pm, Monday, 24'th Jan 2022 Seeking Alpha
The FDA is planning to restrict the COVID-19 monoclonal antibody therapies developed by Regeneron <> and Eli Lilly <> citing their lack of efficacy against the
Regeneron (REGN) Rides on Solid Product Portfolio: Should You Buy?
11:35am, Friday, 21'st Jan 2022
Regeneron (REGN) is expected to maintain momentum on the back of a solid and diverse portfolio. The promising pipeline also sets the stage for further growth.
